{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Small+Intestine+Cancer&page=4",
    "query": {
      "condition": "Advanced Small Intestine Cancer",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 371,
    "total_pages": 38,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Small+Intestine+Cancer&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Small+Intestine+Cancer&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T01:57:55.227Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06983743",
      "title": "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ERAS-0015",
          "type": "DRUG"
        },
        {
          "name": "ERAS-0015 in combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Erasca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 600,
      "start_date": "2025-06-05",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-30T01:57:55.227Z",
      "location_count": 9,
      "location_summary": "Santa Rosa, California • Aurora, Colorado • Sarasota, Florida + 6 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06983743"
    },
    {
      "nct_id": "NCT01520389",
      "title": "Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Colorectal Cancer",
        "Squamous Cell Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "MM-151",
          "type": "DRUG"
        },
        {
          "name": "MM-151 + irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merrimack Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2012-01",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2018-03-21",
      "last_synced_at": "2026-10-30T01:57:55.227Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Lafayette, Indiana • Buffalo, New York + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01520389"
    },
    {
      "nct_id": "NCT00003674",
      "title": "Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Lung Cancer",
        "Prostate Cancer",
        "Veno-occlusive Disease"
      ],
      "interventions": [
        {
          "name": "dalteparin",
          "type": "DRUG"
        },
        {
          "name": "standard therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 141,
      "start_date": "1998-12",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2016-07-13",
      "last_synced_at": "2026-10-30T01:57:55.227Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003674"
    },
    {
      "nct_id": "NCT01803282",
      "title": "Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Non-small Cell Lung Cancer",
        "Esophagogastric Cancer",
        "Colorectal Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Andecaliximab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 236,
      "start_date": "2013-03-29",
      "completion_date": "2019-04-23",
      "has_results": true,
      "last_update_posted_date": "2020-06-02",
      "last_synced_at": "2026-10-30T01:57:55.227Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01803282"
    },
    {
      "nct_id": "NCT07327489",
      "title": "Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer",
        "Immunotherapy",
        "Advanced Solid Tumors Cancer",
        "Bladder Cancer",
        "TNBC, Triple Negative Breast Cancer",
        "Colorectal Cancer",
        "DMMR Colorectal Cancer",
        "MSI-H Colorectal Cancer",
        "Endometrial Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Liver Cancer",
        "NSCLC (Non-small-cell Lung Cancer)",
        "Skin Cancer",
        "Melanoma (Skin Cancer)"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Elephas",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2025-04-14",
      "completion_date": "2038-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-10-30T01:57:55.227Z",
      "location_count": 8,
      "location_summary": "Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Frederick",
          "state": "Maryland"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07327489"
    },
    {
      "nct_id": "NCT04028479",
      "title": "The Registry of Oncology Outcomes Associated With Testing and Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenocarcinoma",
        "Adenocystic Carcinoma",
        "Anal Cancer",
        "Appendix Cancer",
        "Brain Tumor",
        "Glioblastoma",
        "Astrocytoma",
        "Bile Duct Cancer",
        "Cholangiocarcinoma",
        "Bladder Cancer",
        "Bone Cancer",
        "Synovial Sarcoma",
        "Chondrosarcoma",
        "Liposarcoma",
        "Sarcoma, Kaposi",
        "Sarcoma,Soft Tissue",
        "Sarcoma",
        "Osteosarcoma",
        "CNS Cancer",
        "Brain Stem Neoplasms",
        "Breast Cancer",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Rectal Cancer",
        "Colon Cancer",
        "Esophageal Cancer",
        "Esophagus Cancer",
        "Cancer of Colon",
        "Pancreatic Cancer",
        "Cancer of Pancreas",
        "Testis Cancer",
        "Testicular Cancer",
        "Ureter Cancer",
        "Renal Cell Carcinoma",
        "Kidney Cancer",
        "Gestational Trophoblastic Tumor",
        "Head and Neck Neoplasms",
        "Parotid Tumor",
        "Larynx Cancer",
        "Tongue Cancer",
        "Pharynx Cancer",
        "Salivary Gland Cancer",
        "Acute Myeloid Leukemia",
        "Chronic Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Multiple Myeloma",
        "Non Hodgkin Lymphoma",
        "Carcinoid Tumor",
        "Lung Cancer",
        "Neuroendocrine Tumors",
        "Mesothelioma",
        "Thyroid Cancer",
        "Parathyroid Neoplasms",
        "Adrenal Cancer",
        "Small Bowel Cancer",
        "Stomach Cancer",
        "Liver Cancer",
        "Hepatic Cancer",
        "Melanoma",
        "Skin Cancer",
        "Unknown Primary Tumors",
        "Uterine Cancer",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Vaginal Cancer",
        "Penile Cancer",
        "Vulvar Cancer",
        "Waldenstrom Macroglobulinemia",
        "Cancer, Advanced",
        "Thymus Cancer",
        "Nasopharyngeal Carcinoma",
        "Multiple Endocrine Neoplasia",
        "Pheochromocytoma",
        "Small Cell Carcinoma",
        "Pulmonary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biomarker Testing (L)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Systemic Treatment (T)",
          "type": "DRUG"
        },
        {
          "name": "Patient Reported Outcomes (P)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Taproot Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 167,
      "start_date": "2021-05-05",
      "completion_date": "2024-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-10-30T01:57:55.227Z",
      "location_count": 2,
      "location_summary": "Idaho Falls, Idaho • Laredo, Texas",
      "locations": [
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Laredo",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04028479"
    },
    {
      "nct_id": "NCT02729298",
      "title": "First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "EGFR Positive Non-small Cell Lung Cancer",
        "Colorectal Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "BRAF-Mutated Melanoma"
      ],
      "interventions": [
        {
          "name": "TP-0903",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2016-12-14",
      "completion_date": "2022-06-29",
      "has_results": false,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-10-30T01:57:55.227Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02729298"
    },
    {
      "nct_id": "NCT03948763",
      "title": "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Pancreatic Neoplasms",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "V941",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2019-06-26",
      "completion_date": "2022-08-25",
      "has_results": true,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-10-30T01:57:55.227Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03948763"
    },
    {
      "nct_id": "NCT01202409",
      "title": "CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Cancer"
      ],
      "interventions": [
        {
          "name": "Panitumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2010-11-02",
      "completion_date": "2018-07-03",
      "has_results": true,
      "last_update_posted_date": "2020-02-21",
      "last_synced_at": "2026-10-30T01:57:55.227Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01202409"
    },
    {
      "nct_id": "NCT04432857",
      "title": "AN0025 and Pembrolizumab Combination in Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple-negative Breast Cancer",
        "NSCLC, Squamous or Non-Squamous",
        "Urothelial Carcinoma of the Bladder",
        "Microsatellite Stable (MSS) Colorectal Cancer (CRC)",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "AN0025",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adlai Nortye Biopharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2020-08-20",
      "completion_date": "2025-01-30",
      "has_results": false,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-10-30T01:57:55.227Z",
      "location_count": 4,
      "location_summary": "St Louis, Missouri • Houston, Texas • Salt Lake City, Utah + 1 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04432857"
    }
  ]
}